U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. BBS Pharmacy, Inc. dba B&B Pharmacy - 08/31/2017
  1. Warning Letters

CLOSEOUT LETTER

BBS Pharmacy, Inc. dba B&B Pharmacy

Recipient:
BBS Pharmacy, Inc. dba B&B Pharmacy

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

Division of Pharmaceutical Quality Operations IV
19701 Fairchild Road
Los Angeles, CA 92612
 

 
 

VIA UNITED PARCEL SERVICE
SIGNATURE REQUIRED

August 31, 2017

Julie H. Yoon, Pharm.D., Owner
BBS Pharmacy, Inc. dba B&B Pharmacy
10244 Rosecrans Avenue
Bellflower, CA 90706-2602

Dear Dr. Yoon:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL # 45-16] dated September 2, 2016. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV
 

Cc:
Virginia Herold, Executive Officer
California State Board of Pharmacy
1625 N Market Blvd N219
Sacramento, CA 95834

Back to Top